Exosomes: a new perspective in EGFR-mutated lung cancer

Jouida, Amina; McCarthy, Cormac; Fabre, Aurélie; Keane, Michael P.

doi:10.1007/s10555-021-09962-6

Cited by 23 publications

(9 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 152 Exosome‐based detection of EGFR mutation in plasma from NSCLC patients has also achieved favorable diagnostic results. 153 Detection of the T790M mutation on exosomal cfDNA achieved 92% sensitivity and 89% specificity using tumor biopsy results as gold standard. 154 In another study, the sensitivity was 98% for detection of activating EGFR mutations and 90% for EGFR T790M based on exosomal cfDNA.…”

Section: Exosomal Proteins As Diagnostic and Prognostic Biomarkers For Lung Cancermentioning

confidence: 98%

Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics

et al. 2021

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer‐related death worldwide due to diagnosis in the advanced stage and drug resistance in the subsequent treatments. Development of novel diagnostic and therapeutic methods is urged to improve the disease outcome. Exosomes are nano‐sized vehicles which transport different types of biomolecules intercellularly, including DNA, RNA and proteins, and are implicated in cross‐talk between cells and their surrounding microenvironment. Tumor‐derived exosomes (TEXs) have been revealed to strongly influence the tumor microenvironment, antitumor immunoregulatory activities, tumor progression and metastasis. Potential of TEXs as biomarkers for lung cancer diagnosis, prognosis and treatment prediction is supported by numerous studies. Moreover, exosomes have been proposed to be promising drug carriers. Here, we review the mechanisms of exosomal formation and uptake, the functions of exosomes in carcinogenesis, and potential clinical utility of exosomes as biomarkers, tumor vaccine and drug delivery vehicles in the diagnosis and therapeutics of lung cancer.

show abstract

Section: Exosomal Proteins As Diagnostic and Prognostic Biomarkers For Lung Cancermentioning

confidence: 98%

Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Exosomes carry important molecular information since they are secreted from living cells, and in some cases, their analysis could be more informative than cfDNA [ 182 ]. However, there are still challenges to overcome, and further research needs to be undertaken in order to integrate exosome analysis into the liquid biopsy setting…”

Section: Liquid Biopsy Testing In Nsclcmentioning

confidence: 99%

Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer

Buszka

Ntzifa

Owecka

et al. 2022

Cells

View full text Add to dashboard Cite

The treatment of non-small cell lung cancer (NSCLC) has recently evolved with the introduction of targeted therapy based on the use of tyrosine kinase inhibitors (TKIs) in patients with certain gene alterations, including EGFR, ALK, ROS1, BRAF, and MET genes. Molecular targeted therapy based on TKIs has improved clinical outcomes in a large number of NSCLC patients with advanced disease, enabling significantly longer progression-free survival (PFS). Liquid biopsy is an increasingly popular diagnostic tool for treating TKI-based NSCLC. The studies presented in this article show that detection and analysis based on liquid biopsy elements such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and/or tumor-educated platelets (TEPs) can contribute to the appropriate selection and monitoring of targeted therapy in NSCLC patients as complementary to invasive tissue biopsy. The detection of these elements, combined with their molecular analysis (using, e.g., digital PCR (dPCR), next generation sequencing (NGS), shallow whole genome sequencing (sWGS)), enables the detection of mutations, which are required for the TKI treatment. Despite such promising results obtained by many research teams, it is still necessary to carry out prospective studies on a larger group of patients in order to validate these methods before their application in clinical practice.

show abstract

“…LB performed at different post-operative times can quantify the circulating tumor DNA and/or identify the presence of mutations in EGFR, which can point to recurrence or tumor progression [52]. Additionally, apart from CTCs and circulating tumor DNA, blood samples from lung cancer patients can contain other circulating components of strong interest, such as extracellular vesicles (EVs) [53][54][55][56]. Therefore, all cells, including tumor cells, can release EVs in the blood stream, which are broadly divided into ectosomes and exosomes.…”

Section: Which Biological Sample For Evaluation Of the Egfr Status Of Early Stage Nsclc?mentioning

confidence: 99%

“…Therefore, all cells, including tumor cells, can release EVs in the blood stream, which are broadly divided into ectosomes and exosomes. More and more studies have focused on exosomes' assessment in LB because of their potential not only in lung cancer diagnosis and prognosis but also as predictive biomarkers for different treatment in NSCLC patients [53][54][55][56]. The evaluation of the EGFR status with surgical specimens must meet a number of requirements.…”

Section: Which Biological Sample For Evaluation Of the Egfr Status Of Early Stage Nsclc?mentioning

confidence: 99%

EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

Hofman

2021

Cells

View full text Add to dashboard Cite

The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting EGFR mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of biomarkers predictive of the efficacy of different treatments in these patients. Currently, the choice of one or another of these treatments mainly depends on the results of immunohistochemistry for PD-L1 and of the status of EGFR and ALK. This new development has led to the setup of different analyses for clinical and molecular pathology laboratories, which have had to rapidly integrate a number of new challenges into daily practice and to establish new organization for decision making. This review outlines the impact of the management of biological samples in laboratories and discusses perspectives for pathologists within the framework of EGFR TKIs in early stage NSCLC.

show abstract

Exosomes: a new perspective in EGFR-mutated lung cancer

Cited by 23 publications

References 135 publications

Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics

Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics

Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer

EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

Contact Info

Product

Resources

About